Bio Pharma Dive

AUGUST 23, 2022

At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.

RNA 327

RNA Medicine Drugs 327

Bio Pharma Dive

JANUARY 3, 2024

The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.

RNA 171

RNA Drugs Development 171

Bio Pharma Dive

NOVEMBER 9, 2021

The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.

RNA 359

RNA Medicine Drugs Research 359

Bio Pharma Dive

SEPTEMBER 7, 2022

“We see a huge opportunity in the setting of RNA-based therapies to overcome some of the shortcomings that have been there with the first generation of RNA companies,” said former Alnylam CEO and Orbital Therapeutics co-founder John Maraganore.

RNA 228

RNA Drugs 228

Pharmaceutical Technology

DECEMBER 13, 2023

Daiichi Sankyo plans to leverage the French startup’s technology to develop its RNA-targeted therapeutics pipeline.

RNA 147

RNA Drugs Development 147

Pharma Times

APRIL 29, 2024

The method has the potential to be used to deliver RNA to the bloodstream for a range of diseases

RNA 111

RNA Drugs 111

BioSpace

APRIL 21, 2024

Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.

RNA 112

RNA Development Drugs Research 112

Pharmaceutical Technology

MARCH 1, 2023

Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.

RNA 147

RNA Vaccination Vaccine Genetics 147

Bio Pharma Dive

MAY 23, 2023

Staffed by many former Alnylam and Moderna employees, the startup is developing technologies that could be useful in a variety of RNA drugmaking methods.

RNA 183

RNA Drugs Development 183

Bio Pharma Dive

JULY 17, 2023

For $500 million, Novartis will acquire DTx Pharma and its preclinical neurological disease drugs, marking the Swiss company’s latest investment in gene-silencing medicines.

Gene Silencing 246

Gene Silencing RNA Drugs Gene 246

pharmaphorum

DECEMBER 13, 2023

Daiichi Sankyo taps Depixus to speed RNA drug discovery Phil.Taylor Wed, 13/12/2023 - 10:43 Bookmark this

RNA 105

RNA Drugs 105

Bio Pharma Dive

JANUARY 6, 2021

The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.

RNA 164

RNA Drugs Development 164

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2023

The Drug Controller General of India (DCGI) has added in-vitro diagnostic (IVD) medical devices including those for diagnosis of Covid-19, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) extraction kits, among others into the Class C risk category under the Medical Devices Rules (MDR), 2017.

RNA 170

RNA DNA In-Vitro Drugs 170

Pharmaceutical Technology

OCTOBER 11, 2022

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.

RNA 130

RNA Development Genome Genomics 130

Bio Pharma Dive

AUGUST 9, 2023

The Flagship-backed company claims its technology can create genetic drugs that work broadly to treat diseases caused by “stop” mutations.

RNA 130

RNA Drugs Genetics 130

Pharmaceutical Technology

JULY 29, 2022

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs).

RNA 245

RNA Gene Expression Gene Gene Therapy 245

Bio Pharma Dive

OCTOBER 9, 2023

The agency rejected Alnylam’s application for approval of its medicine patisiran in people with a rare heart condition, setting back the company’s plans.

RNA 156

RNA Drugs Medicine 156

Bio Pharma Dive

SEPTEMBER 23, 2022

The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing.

RNA 305

RNA Medicine Drugs 305

Bio Pharma Dive

JANUARY 23, 2024

J&J and Bristol Myers joined the latest funding round for the startup, which was led by the newly launched Mirae Asset Capital Life Science.

RNA 164

RNA Life Science Drugs 164

Drug Discovery World

SEPTEMBER 12, 2022

As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. The post New solution to boost RNA drug development appeared first on Drug Discovery World (DDW).

RNA 52

RNA Development Gene Therapy Drugs 52

pharmaphorum

MAY 8, 2024

Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively. Now, a study suggests simple blood test could help predict those who will benefit.

RNA 103

RNA Drugs 103

Bio Pharma Dive

AUGUST 18, 2022

The company plans to soon seek approval of a once-monthly preventive drug for hereditary angioedema, a disease other drugmakers are targeting with gene editing and RNA medicines.

Gene Editing 264

Gene Editing RNA Drugs Gene 264

Drug Discovery World

SEPTEMBER 18, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Research Drugs 52

Bio Pharma Dive

NOVEMBER 28, 2023

Tuesday’s deal signals the pharmaceutical giant's confidence in Avidity Biosciences and its so-called antibody oligonucleotide conjugates.

RNA 156

RNA Antibody Drugs 156

Drug Discovery World

AUGUST 28, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Research Drugs 52

STAT News

NOVEMBER 14, 2022

Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA.    On Monday, the company announced a partnership with Metagenomi to kickstart these efforts.

Gene Editing 98

Gene Editing RNA Gene Drugs 98

Drug Discovery World

SEPTEMBER 11, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Research Drugs 52

Drug Discovery World

DECEMBER 5, 2022

The consequence is the identification of drug targets that are not relevant to the biological process under study. . Join DDW for this free event, Broadening the horizon of drug discovery: use of unperturbed, native state cells to uncover true biological targets at single-cell level , which is supported by LevitasBio. Camila Egidio.

RNA 52

RNA Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Artificial Intelligence (AI) has been enthusiastically adopted by the drug discovery sector as a tool for shortening drug discovery cycle times and increasing success rates.

RNA 52

RNA Medicine Engineer Drugs 52

Bio Pharma Dive

JANUARY 17, 2024

The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.

RNA 188

RNA Drugs Development 188

pharmaphorum

SEPTEMBER 15, 2023

6th RNA-Targeted Drug Discovery & Development Summit – December 12-14, Boston, MA Mike.Hammerton Fri, 15/09/2023 - 08:21 Bookmark this

RNA 52

RNA Development Drugs 52

pharmaphorum

NOVEMBER 1, 2022

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Date: 8 – 9 February 2023.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

Drug Discovery World

SEPTEMBER 4, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 52

RNA Research Drugs 52

Drug Discovery World

AUGUST 3, 2023

Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital amaurosis 10 due to the c.2991+1655A>G It has been granted orphan drug designation in the US and the EU and received fast-track and rare paediatric disease designations from the FDA.

RNA 52

RNA Gene Development Drugs 52

Bio Pharma Dive

AUGUST 16, 2022

The pharmaceutical company has formed an alliance with Orna and invested $100 million in its Series B round, hoping the young biotech’s approach could lead to multiple new vaccines and drugs.

RNA 280

RNA Vaccination Vaccine Drugs 280

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. The post Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class appeared first on.

RNA 98

RNA Drugs Protein Immune Response 98

Scienmag

MAY 3, 2022

LA JOLLA, CA—Scientists at Scripps Research have unveiled a new software tool for studying RNA (ribonucleic acid) molecules, which have a host of critical roles in organisms. The app […].

RNA 77

RNA Development Research Drugs 77